Literature DB >> 16118810

Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales.

Keith O'Rourke, Douglas G Altman.   

Abstract

In a recent Statistics in Medicine paper, Warn, Thompson and Spiegelhalter (WTS) made a comparison between the Bayesian approach to the meta-analysis of binary outcomes and a popular Classical approach that uses summary (two-stage) techniques. They included approximate summary (two-stage) Bayesian techniques in their comparisons in an attempt undoubtedly to make the comparison less unfair. But, as this letter will argue, there are techniques from the Classical approach that are closer-those based directly on the likelihood-and they failed to make comparisons with these. Here the differences between Bayesian and Classical approaches in meta-analysis applications reside solely in how the likelihood functions are converted into either credibility intervals or confidence intervals. Both summarize, contrast and combine data using likelihood functions. Conflating what Bayes actually offers to meta-analysts-a means of converting likelihood functions to credibility intervals-with the use of likelihood functions themselves to summarize, contrast and combine studies is at best misleading. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 16118810     DOI: 10.1002/sim.2115

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

Review 1.  Comparison of the efficacy and safety of 3 treatments for patients with osteoporotic vertebral compression fractures: A network meta-analysis.

Authors:  Song Zhao; Chang-Yan Xu; Ao-Ran Zhu; Long Ye; Long-Long Lv; Long Chen; Qi Huang; Feng Niu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

2.  Chinese Herbal Medicine to Treat Allergic Rhinitis: Evidence From a Meta-Analysis.

Authors:  Yuan Zhang; Luo Zhang; Xu Zhang; Feng Lan
Journal:  Allergy Asthma Immunol Res       Date:  2018-01       Impact factor: 5.764

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.